首頁 > 市場調查報告書 > 製藥

處方藥循環系統

市場調查報告書

商品編碼

1789398

Eliquis 市場：依適應症、療效、年齡層、劑型、通路和地區分類

Eliquis Market, By Indication, By Strength, By Age Group, By Dosage Form, By Distribution Channel, By Geography

出版日期: 2025年07月04日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

Eliquis 市場規模預計在 2025 年達到 79 億美元，預計在 2032 年達到 113 億美元，2025 年至 2032 年的複合年成長率為 5.2%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	79億美元
效能數據	2020-2024	預測期	2025-2032
預測期：2025-2032年複合年成長率：	5.20%	2032年預測	113億美元

全球 Eliquis 市場是製藥業的關鍵領域，專注於世界上使用最廣泛的抗凝血劑之一。 Eliquis（Apixaban）由百時美施貴寶和輝瑞開發，是一種直介面服抗凝血劑 (DOAC)，屬於 Xa 因子抑制劑類。這種突破性的治療方法改變了各種血栓性栓塞症的治療前景，包括心房顫動、深層靜脈栓塞症和肺動脈栓塞。該市場包括 Eliquis 在多個治療應用和地區的生產、分銷和商業化。隨著全球醫療保健系統優先改善患者預後並尋求Warfarin等傳統抗凝血劑的替代品，Eliquis 因其卓越的療效、降低的出血風險和無需常規監測而成為首選。市場發展的特點是醫療保健專業人員的採用率不斷提高、適應症不斷擴大以及患者對先進抗凝血治療的認知不斷提高。

市場動態

全球 Eliquis 市場受多種因素驅動，推動其在國際醫療保健市場的擴張。全球心房顫動、靜脈血栓栓塞症和其他心血管疾病的盛行率不斷上升，尤其是人口老化和生活方式相關風險因素加劇了這一趨勢，這是一個根本促進因素。與Warfarin等傳統抗凝血劑相比，醫療保健提供者越來越青睞 Eliquis，因為 Eliquis 具有出色的安全性、可預測的藥物動力學，並且無需常規監測，從而顯著提高了患者的依從性和生活品質。大量臨床試驗數據證明，Eliquis 在降低中風風險和全身性栓塞方面有效，這已在循環系統和基層醫療醫生中得到廣泛採用。然而，市場面臨重大限制，包括 Eliquis 與非專利抗凝血劑相比價格較高，限制了其在價格敏感市場和預算受限的醫療保健系統中的可用性。專利到期擔憂和潛在的學名藥競爭對市場獨佔性構成長期威脅，而某些患者群體中的不利事件和禁忌症則限制了其普遍應用。儘管存在這些挑戰，但隨著治療適應症的擴大、新興市場對深度抗凝血治療認知的提高以及新興經濟體醫療支出的增加，重大機會正在湧現。精準醫療方法和個人化抗凝血治療的日益普及為公司提供了進一步的成長途徑，而戰略夥伴關係關係和在服務欠缺地區的市場擴張舉措，則為不斷發展的抗凝血領域中的相關人員帶來了巨大的收益潛力。

本次調查的主要特點

本報告對全球 Eliquis 市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和年複合成長率（CAGR%）。
它還強調了各個領域的潛在商機，並說明了針對該市場的引人注目的投資提案。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數概述了全球 Eliquis 市場的主要企業。
本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球 Eliquis 市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
透過用於分析全球 Eliquis 市場的各種策略矩陣，相關人員可以輕鬆做出決策。

降低非瓣膜性心房顫動患者中風和全身性栓塞的風險
髖關節或膝關節關節重建術後深層靜脈栓塞症的預防
深層靜脈栓塞症
肺動脈栓塞
降低復發性深層靜脈栓塞症和肺動脈栓塞的風險
降低兒科患者靜脈血栓栓塞症(VTE) 和復發性 VTE 的風險

5. 2020 年至 2032 年全球 Eliquis 市場（按效力）

2.5mg
5mg

6. 2020 年至 2032 年按年齡分類的全球 Eliquis 市場

孩子們
成人

7. 2020 年至 2032 年全球 Eliquis 市場（以劑型分類）

口服錠劑
口服懸浮液

8. 2020 年至 2032 年按分銷管道分類的全球 Eliquis 市場

醫院藥房
零售藥局
網路藥局

9. 2020 年至 2032 年按地區分類的全球 Eliquis 市場

北美洲
拉丁美洲
歐洲
亞太地區
中東
非洲

第10章競爭格局

Pfizer Inc.
Bristol-Myers Squibb Company

第 11 章分析師建議

機會
分析師觀點
Coherent Opportunity Map

第12章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI8193

Eliquis Market is estimated to be valued at USD 7.90 Bn in 2025 and is expected to reach USD 11.30 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.2% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 7.90 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.20%	2032 Value Projection:	USD 11.30 Bn

The global Eliquis market represents a critical segment within the pharmaceutical industry, focusing on one of the most widely prescribed anticoagulant medications worldwide. Eliquis (apixaban), developed by Bristol Myers Squibb and Pfizer, is a direct oral anticoagulant (DOAC) that belongs to the factor Xa inhibitor class of medications. This revolutionary drug has transformed the treatment landscape for various thromboembolic conditions, including atrial fibrillation, deep vein thrombosis, and pulmonary embolism. The market encompasses the production, distribution, and commercialization of Eliquis across multiple therapeutic applications and geographical regions. As healthcare systems globally prioritize improved patient outcomes and seek alternatives to traditional anticoagulants like warfarin, Eliquis has emerged as a preferred choice due to its superior efficacy profile, reduced bleeding risks, and elimination of routine monitoring requirements. The market's evolution is characterized by increasing adoption rates among healthcare providers, expanding indications for use, and growing patient awareness about advanced anticoagulation therapies.

Market Dynamics

The global Eliquis market is primarily driven by several compelling factors that collectively fuel its expansion across international healthcare markets. The increasing prevalence of atrial fibrillation, venous thromboembolism, and other cardiovascular conditions worldwide serves as a fundamental growth driver, particularly amplified by aging demographics and lifestyle-related risk factors. Healthcare providers' growing preference for Eliquis over traditional anticoagulants like warfarin stems from its superior safety profile, predictable pharmacokinetics, and elimination of routine monitoring requirements, significantly improving patient compliance and quality of life. The drug's proven efficacy in reducing stroke risk and systemic embolism, supported by extensive clinical trial data, continues to drive adoption among cardiologists and primary care physicians. However, the market faces notable restraints including the high cost of Eliquis compared to generic anticoagulants, which creates accessibility challenges in price-sensitive markets and healthcare systems with budget constraints. Patent expiration concerns and potential generic competition pose long-term threats to market exclusivity, while adverse events and contraindications in certain patient populations limit universal applicability. Despite these challenges, significant opportunities emerge from expanding therapeutic indications, growing awareness about advanced anticoagulation therapies in emerging markets, and increasing healthcare expenditure in developing economies. The rising adoption of precision medicine approaches and personalized anticoagulation therapy presents additional growth avenues, while strategic partnerships and market expansion initiatives in underserved geographical regions offer substantial revenue potential for stakeholders in the evolving anticoagulant therapeutic landscape.

Key Features of the Study

This report provides in-depth analysis of the global Eliquis market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Eliquis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bristol Myers Squibb, Pfizer Inc., and other major pharmaceutical distributors and generic manufacturers
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global Eliquis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Eliquis market

Market Segmentation

Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation
- Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery
- Deep Vein Thrombosis
- Pulmonary Embolism
- Reduction in the Risk of Recurrence of Deep Vein Thrombosis and Pulmonary Embolism
- Venous Thromboembolism (VTE) and Reduction in the Risk of Recurrent VTE in Pediatric Patients
Strength Insights (Revenue, USD Bn, 2020 - 2032)
- 5 mg
- 5 mg
Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
- Oral Tablet
- Oral Suspension
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Pfizer Inc.
- Bristol-Myers Squibb Company

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Eliquis Market, By Indication
- Global Eliquis Market, By Strength
- Global Eliquis Market, By Age Group
- Global Eliquis Market, By Dosage Form
- Global Eliquis Market, By Distribution Channel
- Global Eliquis Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends
Epidemiology
Adherence rate in U.S.
Switch analysis in U.S.
Patent Expiry Scenario

4. Global Eliquis Market, By Indication, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Deep Vein Thrombosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Pulmonary Embolism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Reduction in the Risk of Recurrence of Deep Vein Thrombosis and Pulmonary Embolism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Venous Thromboembolism (VTE) and Reduction in the Risk of Recurrent VTE in Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Eliquis Market, By Strength, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
5 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Eliquis Market, By Age Group, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Eliquis Market, By Dosage Form, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral Tablet
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Oral Suspension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Eliquis Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Eliquis Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies